GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » EV-to-EBIT

TTOO (T2 Biosystems) EV-to-EBIT : -0.68 (As of Dec. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, T2 Biosystems's Enterprise Value is $26.85 Mil. T2 Biosystems's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-39.77 Mil. Therefore, T2 Biosystems's EV-to-EBIT for today is -0.68.

The historical rank and industry rank for T2 Biosystems's EV-to-EBIT or its related term are showing as below:

TTOO' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.82   Med: -2.62   Max: -0.65
Current: -0.68

During the past 12 years, the highest EV-to-EBIT of T2 Biosystems was -0.65. The lowest was -12.82. And the median was -2.62.

TTOO's EV-to-EBIT is ranked worse than
100% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.99 vs TTOO: -0.68

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. T2 Biosystems's Enterprise Value for the quarter that ended in Sep. 2024 was $53.82 Mil. T2 Biosystems's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-39.77 Mil. T2 Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -73.89%.


T2 Biosystems EV-to-EBIT Historical Data

The historical data trend for T2 Biosystems's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems EV-to-EBIT Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.84 -4.80 -2.69 -1.07 -1.33

T2 Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.53 -1.33 -1.47 -2.43 -1.35

Competitive Comparison of T2 Biosystems's EV-to-EBIT

For the Diagnostics & Research subindustry, T2 Biosystems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's EV-to-EBIT falls into.



T2 Biosystems EV-to-EBIT Calculation

T2 Biosystems's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=26.854/-39.766
=-0.68

T2 Biosystems's current Enterprise Value is $26.85 Mil.
T2 Biosystems's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


T2 Biosystems  (NAS:TTOO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

T2 Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=-39.766/53.818397
=-73.89 %

T2 Biosystems's Enterprise Value for the quarter that ended in Sep. 2024 was $53.82 Mil.
T2 Biosystems's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


T2 Biosystems EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems Business Description

Traded in Other Exchanges
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
Executives
David B Elsbree director C/O ACME PACKET, INC., 100 CROSBY DRIVE, BEDFORD MA 01730
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184